Lucid Diagnostics Starts Collecting Medicare Payment for EsoGuard, Closes $15M Preferred Financing
LUCD sits 70% above its 52-week low of $0.303 on elevated volume (18× avg).
Summary
Lucid Diagnostics is now getting paid by Medicare for EsoGuard, the first real revenue channel for its esophageal cancer test after years of reimbursement groundwork. The company also closed a $15 million financing through 15,000 Series C convertible preferred shares at $1,000 each, convertible at $0.3519 — a conversion price well below the current share price, so expect dilution as those convert. This follows the September 22 8-K laying out three reimbursement milestones and the August 13 8-K noting the first local coverage policy. The cash matters because the last 10-Q flagged going concern doubt and a debt waiver that expired August 22. The Nasdaq notice from October 12 — 30 straight closes under $1.00 — still hangs over the stock, and the new preferred adds to a share count already swollen by more than 59 million shares of dilution.
At the time of this announcement, LUCD was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.6M. The 52-week trading range was $0.30 to $1.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.